Business Description
Alaunos Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US98973P1012
Share Class Description:
TCRT: Ordinary SharesDescription
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.1 | |||||
| Equity-to-Asset | 0.81 | |||||
| Debt-to-Equity | 0.31 | |||||
| Debt-to-EBITDA | -0.06 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -284.85 | |||||
| Beneish M-Score | 389.79 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -72.4 | |||||
| 3-Year EPS without NRI Growth Rate | -69.1 | |||||
| 3-Year FCF Growth Rate | -81.1 | |||||
| 3-Year Book Growth Rate | -64.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 89.73 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 78.01 | |||||
| 9-Day RSI | 64.46 | |||||
| 14-Day RSI | 55.7 | |||||
| 6-1 Month Momentum % | -82.98 | |||||
| 12-1 Month Momentum % | -85.18 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.16 | |||||
| Quick Ratio | 5.16 | |||||
| Cash Ratio | 2.72 | |||||
| Days Sales Outstanding | 152.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.8 | |||||
| Shareholder Yield % | 355.36 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -225033.33 | |||||
| Net Margin % | -318833.33 | |||||
| FCF Margin % | -289300 | |||||
| ROE % | -189.69 | |||||
| ROA % | -144.17 | |||||
| ROIC % | -362.68 | |||||
| 3-Year ROIIC % | -264.84 | |||||
| ROC (Joel Greenblatt) % | -548.96 | |||||
| ROCE % | -182.14 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 610 | |||||
| PB Ratio | 1.03 | |||||
| Price-to-Tangible-Book | 1.03 | |||||
| EV-to-EBIT | 0.11 | |||||
| EV-to-EBITDA | 0.12 | |||||
| EV-to-Revenue | -359.17 | |||||
| EV-to-Forward-Revenue | 4293.85 | |||||
| EV-to-FCF | 0.12 | |||||
| Price-to-Net-Current-Asset-Value | 1.03 | |||||
| Price-to-Net-Cash | 2.52 | |||||
| Earnings Yield (Greenblatt) % | 909.09 | |||||
| FCF Yield % | -444.28 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TCRT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Alaunos Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.006 | ||
| EPS (TTM) ($) | -12.708 | ||
| Beta | -1.89 | ||
| Volatility % | 171.61 | ||
| 14-Day RSI | 55.7 | ||
| 14-Day ATR ($) | 0.187813 | ||
| 20-Day SMA ($) | 2.153285 | ||
| 12-1 Month Momentum % | -85.18 | ||
| 52-Week Range ($) | 1.95 - 32.849999 | ||
| Shares Outstanding (Mil) | 1.6 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Alaunos Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Alaunos Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Alaunos Therapeutics Inc Frequently Asked Questions
What is Alaunos Therapeutics Inc(TCRT)'s stock price today?
The current price of TCRT is $2.44. The 52 week high of TCRT is $32.85 and 52 week low is $1.95.
When is next earnings date of Alaunos Therapeutics Inc(TCRT)?
The next earnings date of Alaunos Therapeutics Inc(TCRT) is 2024-11-14 Est..
Does Alaunos Therapeutics Inc(TCRT) pay dividends? If so, how much?
Alaunos Therapeutics Inc(TCRT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers